

1787MO

Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC)

R. Dziadziuszko¹, B.J. Solomon², Y-L. Wu³, J.S. Ahn⁴, M. Nishio⁵, D.H. Lee⁶, J-S. Lee⁷, W-Z. Zhong³, H. Horinouchi⁸, W. Mao⁹, M.J. Hochmair¹⁰, F. de Marinis¹¹, M.R. Migliorino¹², I. Bondarenko¹³, T. Xu¹⁴, A. Cardona Gavaldon¹⁵, A. Scalori¹⁶, V.A. McNally¹⁶, A.A. Higginson¹⁷, F. Barlesi¹⁸

¹ Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland, ² Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia, ³ Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, ⁴ Department of Hematology & Oncology, Samsung Medical Center, Seoul, Republic of Korea, ⁵ Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, ⁶ Department of Oncology, Asan Medical Center, Seoul, Republic of Korea, ⁷ Division of Hematology and Medical Oncology, Seoul National University Bundang Hospital, Seongnam-Si, Republic of Korea, ⁸ Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan, ⁹ Department of Thoracic Surgery, Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, China, ¹⁰ Department of Respiratory & Critical Care Medicine, Klinik Floridsdorf, Karl-Landsteiner-Institute for Lung Research and Pulmonary Oncology, Vienna, Austria, ¹¹ Department of Thoracic Oncology, European Institute of Oncology (IRCSS), Milan, Italy, ¹² Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy, ¹³ Oncology And Medical Radiology Department, Dnipropetrovsk Medical Academy, Dnipro, Ukraine, ¹⁴ Department of Clinical Science, Roche (China) Holding Ltd, Shanghai, China, ¹⁵ Data and Statistical Sciences, F. Hoffmann-La Roche Ltd, Basel, Switzerland, ¹⁶ PD Oncology, Roche Products Ltd, Welwyn Garden City, United Kingdom, ¹⁷ PD Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland ¹⁸ Department of Medical Oncology, International Center for Thoracic Cancers (CICT), Villejuif, France

Background

Alectinib, a potent oral ALK tyrosine kinase inhibitor with efficacy in the central nervous system (CNS), is standard of care for pts with resected, stage IB–IIIA, ALK+ NSCLC. At the primary analysis of the phase III, randomised, open-label ALINA (NCT03456076) study, significant disease-free survival (DFS) benefit was seen with alectinib vs chemo (hazard ratio [HR]: 0.24; 95% CI 0.13–0.43; p<0.001). We present updated data for ALINA with 20 months of additional follow-up.

Methods

Eligible pts were aged ≥18 years with completely resected, stage IB–IIIA, ALK+ NSCLC (per UICC/AJCC 7th edition). Pts were randomised 1:1 to receive oral alectinib (600 mg) twice daily for up to 24 months or platinum-based chemo for four 21-day cycles, and stratified by stage (IB vs II vs IIIA) and race (Asian vs non-Asian). Primary endpoint: investigator-assessed DFS in the stage II–IIIA and intent-to-treat (ITT; stage IB–IIIA) populations. Secondary/exploratory endpoints: overall survival (OS), time to CNS-DFS, and safety.

Results

At the efficacy data cutoff (8 Dec 2024), median follow-up in the ITT population was 47 and 48 months with alectinib and chemo, respectively. A sustained, clinically meaningful DFS benefit was seen with alectinib vs chemo in both the stage II–IIIA (HR 0.36; 95% CI: 0.23–0.56) and ITT (HR 0.35; 95% CI: 0.23–0.54) populations (Table). A clinically meaningful CNS-DFS benefit was maintained in the ITT population (HR 0.37; 95% CI 0.19–0.74); OS data remain immature. All pts had completed treatment at the safety cutoff (19 Oct 2023); safety data were highly consistent with the primary analysis (Table) with no new safety signals. Table: 1787MO

DFS	Stage II–IIIA		ITT (stage IB–IIIA)	
	Alectinib (n=116)	Chemo (n=115)	Alectinib (n=130)	Chemo (n=127)
Events, %	25.0	50.4	23.8	49.6
Median, months (95% CI)	NE (59.6–NE)	41.4 (30.6–67.2)	NE (NE–NE)	41.4 (30.6–NE)
Stratified HR(95% CI)	0.36 (0.23–0.56)		0.35 (0.23–0.54)	
48-month rate, %	74.5	46.3	75.5	47.0
60-month rate, %	62.7	41.2	64.8	42.1
Safety	Alectinib(n=128) Chemo(n=120)			
Median treatment duration, months	24.0	2.1		

DFS	Stage II–III A	ITT (stage IB–III A)
	Alectinib (n=116)	Chemo (n=115)
Pts with ≥1 AE, %	98.4	93.3
Grade 3–4*	30.5	30.8
Serious	14.1	8.3
Serious related	1.6	6.7
Leading to dose reduction	25.0	10.0
Leading to dose interruption	28.1	18.3
Leading to treatment withdrawal	5.5	12.5

*No Grade 5 AEs in either treatment arm. AE, adverse event; NE, not evaluable.

Conclusions

After ≥3 years of follow-up, alectinib continued to show a clinically meaningful DFS benefit and safety data remain consistent with the well-established, manageable profile, reinforcing adjuvant alectinib as standard of care for pts with resected *ALK+* NSCLC.

Clinical trial identification

NCT03456076.

Editorial acknowledgement

This study is sponsored by F. Hoffmann-La Roche Ltd. Third party medical writing assistance, under the direction of the authors, was provided by Neave Baldwin, BSc, of Ashfield MedComms, an Inizio company, and was funded by F. Hoffmann-La Roche Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.

Funding

F. Hoffmann-La Roche Ltd.

Disclosure

R. Dziadziuszko: Financial Interests, Personal, Invited Speaker: Roche, Pfizer, Amgen; Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Takeda, Novartis, MSD, Bristol Myers Squibb, Pfizer. B.J. Solomon: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Merck, Bristol Myers Squibb; Financial Interests, Institutional, Invited Speaker: Pfizer; Financial Interests, Personal, Advisory Board: Amgen, Roche-Genentech, Eli Lilly, Takeda, Janssen; Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche/Genentech; Financial Interests, Personal, Full or part-time Employment, Employed as a consultant Medical Oncologist at Peter MacCallum Cancer Centre: Peter MacCallum Cancer Centre; Financial Interests, Personal, Member of Board of Directors: Cancer Council of Victoria, Thoracic Oncology Group of Australasia; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Steering Committee Member, Principal Investigator and Steering committee Chair: Roche/Genentech, Pfizer; Financial Interests, Institutional, Steering Committee Member: Novartis. Y. Wu: Non-Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Takeda; Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Hengrui, Merck, MSD, Pfizer, Roche, Sanofi; Non-Financial Interests, Personal, Principal Investigator: AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Hengrui, Merck, MSD, Pfizer, Roche; Financial Interests, Institutional, Research Grant: AstraZeneca, BMS, Boehringer Ingelheim. J.S. Ahn: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Role: Immuneoncia, Daiichi Sankyo, Sankyo Korea, Pfizer Korea, Yuhan, Pharmbio Korea, Therapex, Guardant; Financial Interests, Personal, Invited Speaker: BMS, LG Chemical, Daiichi Sankyo Korea, Kokwon Medical, Takeda Pharma, Novartis Korea, Yuhan, Samyang, Amgen Korea, Boryung, BC World, Roche Korea, Menarini Korea, Pfizer, Lilly Korea, Boehringer Ingelheim, Kyowa Kirin, AstraZeneca Korea, Bayer Korea. M. Nishio: Financial Interests, Personal, Invited Speaker, lectures fee: Ono Pharmaceuticals, Amgen; Financial Interests, Personal, Invited Speaker, lectures: Chugai Pharmaceutical, Taiho Pharmaceutical, Bristol Myers Squibb, Daiichi Sankyo, AstraZeneca, MSD, Pfizer, Boehringer Ingelheim, Novartis, Merck, Janssen; Financial Interests, Personal, Invited Speaker, lectures.: Lilly. D.H. Lee: Financial Interests, Personal, Advisory Role: AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, ChongKeunDang, Janssen, MSD, Novartis, Ono, Pfizer, Roche, ST Cube, Takeda, BC World Pharm, Yuhan. H. Horinouchi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Eli Lilly, BMS/ONO, Merck Sharp & Dohme, Roche/Chugai, Novartis, Pfizer, Boehringer Ingelheim, Kyowa-Kirin, Nihon Kayaku, AbbVie; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS/ONO, Merck Sharp & Dohme, Roche/Chugai, Amgen, Nihon Kayaku, AbbVie; Financial Interests, Personal, Steering Committee Member: Roche/Chugai, AbbVie, AstraZeneca, Genmab; Financial Interests, Institutional, Research Grant: Roche/Chugai, Merck Sharp & Dohme, Daiichi Sankyo, ONO pharmaceutical, AstraZeneca. M.J. Hochmair: Financial Interests, Personal, Advisory Board: Roche, MSD, Boehringer

Ingelheim, BMS, Takeda, Lilly. F. de Marinis: Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Novartis, Roche/Genentech, MSD, Merck. M.R. Migliorino: Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker: Roche, Novartis, Takeda, AstraZeneca. T. Xu, A. Scalori, V.A. McNally: Financial Interests, Personal, Full or part-time Employment: Roche. A. Cardona Gavaldon: Financial Interests, Personal, Full or part-time Employment: Roche; Financial Interests, Personal, Stocks or ownership: Roche. A.A. Higgerson: Financial Interests, Personal, Full or part-time Employment: Roche; Financial Interests, Personal, Advisory Board, Coaching in nutrition: Aggie Higgerson Health Coaching. F. Barlesi: Financial Interests, Institutional, Other: AbbVie, ACEA, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis, Summit Therapeutics, Takeda. All other authors have declared no conflicts of interest.

© *European Society for Medical Oncology*